Press Releases
Diabetic drug could slow the progression of Parkinson’s disease
· A hallmark of Parkinson's disease is the degeneration of a group of neurons in the brain that release the neurotransmitter dopamine (dopaminergic neurons). By introducing low concentrations of structurally-defined aggregates of alpha synuclein, a key toxic species in Parkinson’s disease, into single dopaminergic neurons, researchers from the University of Warwick have shown these protein aggregates open a specific channel in the cell membrane, reducing neuronal excitability. Furthermore they’ve shown that this can be partially prevented by pre-application of the commonly used anti-diabetic drug, glibenclamide.